The molecular basis for substrate translocation in the Na ⍣ /Cl --dependent neurotransmitter transporters remains elusive. Here we report novel insight into the translocation mechanism by delineation of an endogenous Zn 2⍣ -binding site in the human dopamine transporter (hDAT). In micromolar concentrations, Zn 2⍣ was found to act as a potent, non-competitive blocker of dopamine uptake in COS cells expressing hDAT. In contrast, binding of the cocaine analogue, WIN 35,428, was markedly potentiated by Zn 2⍣ . Surprisingly, these effects were not observed in the closely related human norepinephrine transporter (hNET). A single non-conserved histidine residue (His193) in the large second extracellular loop (ECL2) of hDAT was discovered to be responsible for this difference. Thus, Zn 2⍣ modulation could be conveyed to hNET by mutational transfer of only this residue. His375 conserved between hDAT and hNET, present in the fourth extracellular loop (ECL4) at the top of transmembrane segment VII, was identified as a second major coordinate for Zn 2⍣ binding. These data provide evidence for spatial proximity between His193 and His375 in hDAT, representing the first experimentally demonstrated proximity relationship in an Na ⍣ /Cl --dependent transporter. Since Zn 2⍣ did not prevent dopamine binding, but inhibited dopamine translocation, our data suggest that by constraining movements of ECL2 and ECL4, Zn 2⍣ can restrict a conformational change critical for the transport process.
Introduction
The dopamine transporter (DAT) together with the closely related norepinephrine and serotonin transporters forms a subfamily within the large family of Na ϩ /Cl --dependent transporters . These transporters all share a predicted topology with 12 transmembrane segments ( Figure 1 ) and are functionally characterized by co-transport of substrate with Na ϩ and Cl - (Amara and Kuhar, 1993; Giros and Caron, 1993) . The DAT is localized presynaptically in the nerve terminals and regulates the 4266 © Oxford University Press amount of available dopamine in the synapse by mediating rapid re-uptake of released dopamine (Horn, 1990; Amara and Kuhar, 1993) . In this way, DAT plays a critical role in modulating the physiological effects of dopamine, including regulation of locomotor activity, cognitive functions and neuroendocrine systems (Horn, 1990; Amara and Kuhar, 1993; Giros et al., 1996) . Moreover, DAT is the principal target for the psychostimulatory, addictive drugs, cocaine and amphetamine (Horn, 1990; Giros et al., 1996) .
The tertiary structure of Na ϩ /Cl --dependent transporters is not yet known, and the nature of the molecular processes responsible for the translocation mechanism has not been elucidated. Several studies have attempted to define functional domains both in DAT and in other Na ϩ /Cl --dependent transporters. Site-directed mutagenesis has led to the identification of some residues that are important for either the transport process or for substrate/blocker binding (Kitayama et al., 1992; Pantanowitz, et al., 1993; J.B.Wang et al., 1995; Barker and Blakely, 1996; Bismuth et al., 1997; Chen et al., 1997a,b) . In addition, several groups have constructed chimeric molecules between homologous, but pharmacologically distinct transporter subtypes (Barker et al., 1994; Amara, 1994, 1995; Giros et al., 1994; Stephan et al., 1997) . These studies have provided important information about domains determining substrate and blocker selectivity; however, due to the inherent limitation of the chimeric approach, they have not given insight into the translocation process, which is believed to be evolutionarily conserved among this class of transporters.
Zn 2ϩ is required for the function of numerous proteins, serving both as a part of the active site in, for example, metallo-enzymes, and acting to stabilize protein domains, such as the Zn 2ϩ finger-binding motif in transcription factors (Vallee and Falchuk, 1993; Schwabe and Klug, 1994) . The structure of many Zn 2ϩ -binding sites is known from X-ray crystallography of Zn 2ϩ -binding proteins and, thus, the geometry of the interaction between Zn 2ϩ and different coordinating residues is well characterized (Vallee and Falchuk, 1993; Schwabe and Klug, 1994) . This, together with the small size of the zinc(II) ion, makes artificially generated Zn 2ϩ -binding sites a highly useful approach for probing structure-function relationships in other proteins (Elling et al., 1995; He et al., 1995; Elling and Schwartz, 1996; Sheikh et al., 1996) . In G protein-coupled receptors, for example, construction of bis-His Zn 2ϩ -binding sites has led to important information about both the organization of the transmembrane helices and their potential movements during receptor activation (Elling et al., 1995; Elling and Schwartz, 1996; Sheikh et al., 1996) .
Interestingly, evidence indicates the presence of naturally occurring Zn 2ϩ -binding sites in several receptor . The transporter contains 12 histidine residues of which eight are non-conserved between hDAT and hNET: His165, His179, His193, His228, His442, His477, His547 and His616 (black circles). Four histidines are conserved between hDAT and hNET: His223, His225, His375 and His444 (shaded circles). The histidine residues examined for coordination of Zn 2ϩ are shown as enlarged circles.
proteins in the brain. These include ionotropic glutamate receptors, some γ-aminobutyric acid (GABA) receptor subtypes and the strychnine-sensitive glycine receptor (Peters et al., 1987; Westbrook and Mayer, 1987; Hollmann et al., 1993; Bloomenthal et al., 1994; Laube et al., 1995) . Moreover, previous data have indicated that Zn 2ϩ can modulate dopamine uptake and DAT blocker binding in rat brain preparations (Richfield, 1993; Bonnet et al., 1994) . In the present study, we provide direct evidence that the human DAT (hDAT), but not the closely related human norepinephrine transporter (hNET), possesses an endogenous, high-affinity Zn 2ϩ -binding site. By identifying two major coordinating histidines residues in this binding site, we obtain interesting new insight into the translocation mechanism and map an important distance constraint in an Na ϩ /Cl --dependent transporter.
Results
Zn 2⍣ inhibits dopamine transport and stimulates WIN 35,428 binding at the dopamine transporter Zn 2ϩ inhibited [ 3 H]dopamine uptake in COS-7 cells expressing hDAT in a biphasic manner (K i , high affinity ϭ 0.8 μM, and K i , low affinity Ͼ1000 μM) ( Figure 2A ; Table I ). The effect of micromolar concentrations of Zn 2ϩ on [ 3 H]dopamine uptake was reversible; thus, 10 min preincubation with 10 μM Zn 2ϩ followed by washing the cells resulted in unchanged [ 3 H]dopamine uptake and Zn 2ϩ inhibition curves as compared with control cells (data not shown). In contrast to hDAT, [ 3 H]dopamine uptake mediated by hNET expressed in COS-7 cells was affected only by millimolar concentrations of Zn 2ϩ ( Figure  2A ; Table I ). This indicates that hDAT but not hNET possesses an endogenous high-affinity Zn 2ϩ -binding site. (Zn 2ϩ ; hDAT wild-type). All experiments were performed three to eight times. Figure 2B ; Table I ). Notably, in COS-7 cell membranes, a similar biphasic effect of Zn 2ϩ on [ 3 H]WIN 35,428 binding was observed for hDAT (data not shown).
The mechanism by which Zn 2ϩ affects dopamine uptake was explored by [ 3 H]dopamine uptake assays in the presence and absence of Zn 2ϩ . Scatchard analysis of the data showed that Zn 2ϩ did not change the K m for dopamine uptake, but caused a dramatic decrease in the V max value. In the presence of 10 μM Zn 2ϩ , the V max value was reduced to~30% of the control level (Figure 3 ). This indicates that Zn 2ϩ acts like a non-competitive blocker of dopamine uptake. We also investigated the mechanism underlying Zn 2ϩ potentiation of [ 3 H]WIN 35,428 binding by performing saturation binding experiments with [ 3 H]WIN 35,428 in the absence and presence of 10 μM Zn 2ϩ (data not shown). The experiments indicated an increase in the apparent B max (148 Ϯ 10%, mean Ϯ SE, n ϭ 3, in the presence of 10 μM Zn 2ϩ as compared with control). In contrast, we did not observe a change in K d (K d ϭ 10 Ϯ 2 nM, mean Ϯ SE, n ϭ 3, in the presence of 10 μM Zn 2ϩ as compared with 12 Ϯ 3 nM, n ϭ 3, in the absence of Zn 2ϩ ).
To investigate whether Zn 2ϩ inhibition of dopamine uptake was due to non-competitive inhibition of either dopamine binding or dopamine translocation, we compared the ability of dopamine to compete for 4). Thus, dopamine can apparently bind with unchanged affinity to the Zn 2ϩ -occupied transporter, indicating that Zn 2ϩ specifically inhibits the translocation process.
Mutation of non-conserved histidine residues
Histidines, cysteines, glutamic acids and aspartic acids are most commonly found as coordinating residues in Zn 2ϩ -binding sites (Vallee and Falchuk, 1993) . In order to investigate the possible nature of the residues involved in Zn 2ϩ binding to hDAT, a series of different cations were tested for their ability to inhibit dopamine uptake. The rank order of potency was consistent with the presence of at least one histidine residue in the Zn 2ϩ -binding site: Zn 2ϩ ϾNi 2ϩ ϾCo 2ϩ ϾCo 3ϩ ϾCd 2ϩ ϾMn 2ϩ (data not shown; Glusker, 1991) . We therefore decided to mutate histidines not conserved between hDAT and hNET ( Figure 1) . Mutation of His165, His179, His228, His477 and His547 on the extracellular side of hDAT to the corresponding residue in hNET (hDAT-H165Y, -H179D, -H228S, -H477T and -H547T; (Table I) . Since His179 is a Glu in hNET and possibly could substitute for the histidine in coordination of Zn 2ϩ , we also mutated this residue to an Ala (hDAT-H179A). Again, no change in Zn 2ϩ sensitivity was found (Table I) . However, mutation of His193 in the second extracellular loop, ECL2, (Figure 1 ) to Lys present in hNET (hDAT-H193K) increased the K i value for Zn 2ϩ inhibition of [ 3 H]dopamine uptake 660-fold ( Figure 5A ; Table I ). Moreover, the potentiation of [ 3 H]WIN 35,428 binding was eliminated ( Figure 5C ; Table I (Table I) . It should be noted that mutation of His165 and His477 reduced the percentage of apparent high-affinity Zn 2ϩ sites from~70 to 40-45% (Table I) . However, we interpret this as an indirect structural effect, since the high-affinity K i value for Zn 2ϩ inhibition did not change (Table I) . Overall, the data imply that His193 is a major coordinate in the endogenous hDAT Zn 2ϩ -binding site and may determine the distinct Zn 2ϩ sensitivity of hDAT and hNET.
Mutation of conserved histidine residues
Three histidines conserved between hDAT and hNET on the extracellular side were mutated to alanines to identify additional coordinates (Figure 1) . Mutation of His223 and His225 in ECL2 together (hDAT-H223A-H225A) did not change Zn 2ϩ susceptibility; however, mutation of His375 to Ala (hDAT-H375A) in ECL4 at the top of transmembrane segment (TM) VII caused a 1000-fold increase in the K i value for Zn 2ϩ inhibition of Table I ). Mutation of His193 and His375 together (hDAT-H193K-H375A) caused a slight further decrease in apparent Zn 2ϩ affinity (Table I) . Neither the single point mutation of His375 nor the double mutation (DAT-H193K-H375A) changed the uptake and binding properties of the transporter (Table I) (Table I) . Taken together, the data suggest that His375 is a second coordinate in the hDAT high-affinity Zn 2ϩ -binding site.
Mutational transfer of Zn 2⍣ susceptibility to the hNET Introducing His193 in hDAT into the corresponding position in hNET (hNET-K189H) resulted in transfer of full Zn 2ϩ susceptibility to the hNET with respect to inhibition of [ 3 H]dopamine uptake ( Figure 6 ). To probe whether we had generated a Zn 2ϩ -binding site in hNET identical to the site in hDAT, we also mutated His372 in hNET corresponding to the conserved His375 in hDAT (hNET-H372A) and combined this mutant with the hNET-K189H mutant (hNET-K189H-H372A). Mutation of His372 in hNET-K189H had the same effect as mutating His375 in hDAT ( Figure 6 ). Figure 6 also shows that in the absence of both histidines (hNET-H372A), Zn 2ϩ sensitivity is slightly lower than in the presence of one of them (hNET and hNET-K189H-H372A). These data strongly support the hypothesis that His193 and His375 in hDAT are coordinates in the same Zn 2ϩ -binding sites. Furthermore, they show that the non-conserved residue, His193, determines the distinct Zn 2ϩ sensitivity of hDAT and hNET with respect to inhibition of 
Discussion
This study provides direct evidence that hDAT possesses an endogenous Zn 2ϩ -binding site involving two histidine residues on the extracellular face of the transporter, His193 and His375. Our data demonstrate that Zn 2ϩ bound to this site acts as a non-competitive blocker of substrate translocation. Concurrently, Zn 2ϩ potentiates binding of the cocaine-like blocker WIN 35,428. These observations support earlier studies in rat brain preparations showing potentiation of blocker binding and inhibition of dopamine uptake by Zn 2ϩ (Richfield, 1993; Bonnet et al., 1994) . Previous studies have also suggested that several other complex membrane proteins in the central nervous system contain endogenous Zn 2ϩ -binding sites, such as ionotropic glutamate receptors, some GABA receptor subtypes and the strychnine-sensitive glycine receptor (Peters et al., 1987; Westbrook and Mayer, 1987; Hollmann et al., 1993; Bloomenthal et al., 1994; Laube et al., 1995) . To date, histidine residues coordinating Zn 2ϩ binding have been identified only in the GABA ρ1 subunit (T.L. and the GABA β1 subunit (Horenstein and Akabas, 1998) ; otherwise, residues coordinating Zn 2ϩ binding in these receptor proteins have, to our knowledge, not yet been identified. Interestingly, artificial Zn 2ϩ -binding sites have recently been generated in other families of membrane proteins and have been shown to be highly useful for probing structure-function relationships (Elling et al., 1995; He et al., 1995; Elling and Schwartz, 1996; Sheikh et al., 1996) .
From crystal structures of Zn 2ϩ -binding proteins, it is known that the average distance between the zinc(II) ion and the coordinating nitrogen of a histidine residue averages 2 Å (Glusker, 1991) . Hence, the identification of two histidines involved in Zn 2ϩ binding suggests that His193 is in close proximity to His375, imposing an important distance constraint in the unknown tertiary structure of the hDAT (Glusker, 1991) . This represents, to our knowledge, the first experimentally supported proximity relationship in an Na ϩ /Cl --dependent transporter. According to the two-dimensional model of hDAT shown in Figure 1 , we would predict that His375 is located at the N-terminus of ECL4 (top of TM VII) and His193 is~26 residues from the top of TM III. Nearly half of the 26 residues between His193 and the top of TM III are believed to form a loop because of the presumed disulfide bridge formed by Cys180-Cys189. This significantly constrains the possible conformational space for His193.
Both Zn 2ϩ inhibition of dopamine uptake and the effect of Zn 2ϩ on [ 3 H]WIN 35,428 binding were biphasic ( Figure  2) . Interestingly, biphasic responses to Zn 2ϩ have also been observed at the strychnine-sensitive glycine receptor with potentiation of the glycine-induced Cl -current by micromolar concentrations and inhibition by millimolar concentrations of Zn 2ϩ (Bloomenthal et al., 1994) . The data were proposed to result from the interaction of Zn 2ϩ with two distinct metal ion-binding sites (Bloomenthal et al., 1994) . In parallel, it is likely that the inhibitory effects of Zn 2ϩ in millimolar concentrations at both hNET and hDAT are due to interaction with a site different from that involved in the effects observed at micromolar concentrations of Zn 2ϩ in hDAT. It should also be considered, however, that the inhibitory effects of Zn 2ϩ in millimolar concentrations may be non-specific, caused by the non-physiological toxic concentrations of Zn 2ϩ (Frederickson, 1989) .
Our data provide clear evidence that the effects of Zn 2ϩ in micromolar (and physiological) concentrations are due to coordination of Zn 2ϩ to at least two histidines in the hDAT. However, Zn 2ϩ concentrations that would be expected to saturate this apparent high-affinity Zn 2ϩ -binding site (~100 μM) only cause 60-70% inhibition of dopamine uptake (Figure 2) . One explanation could be that the transporter can still translocate substrate even when Zn 2ϩ is bound, but only at reduced efficacy (30-40% of normal efficacy). Alternatively, it may reflect the existence of two conformational states of the transporter with distinct Zn 2ϩ sensitivity. We cannot distinguish 4271 between the two hypotheses; however, they are both consistent with the major implication from this study, that Zn 2ϩ non-competitively inhibits substrate translocation by maintaining His193 in ECL2 and His375 in ECL4 at the top of TM VII in close spatial proximity. In other words, our data suggest that by restraining relative movements of ECL2/ECL4, Zn 2ϩ may inhibit a conformational change critical for the translocation process. Interestingly, a critical role for ECL2 in the substrate translocation was proposed recently based on a chimeric exchange of a part of the ECL2 loop between the serotonin transporter (SERT) and the NET (Stephan et al., 1997) .
Even though our data are obtained in vitro, it is tempting to suggest that Zn 2ϩ is a modulator of dopamine transporter activity in vivo. This is consistent with the increasing amount of evidence pointing to Zn 2ϩ as a neuromodulator (Huang, 1997) . It is highly likely that free Zn 2ϩ is present in the synaptic cleft in concentrations required to modulate the function of the hDAT. The basal concentration of Zn 2ϩ in the brain is~10 nM (Frederickson et al., 1984; Frederickson, 1989) ; however, upon neuronal stimulation, Zn 2ϩ has been shown to be released in concentrations of 300 μM (Assaf and Chung, 1984) . Intriguingly, free Zn 2ϩ has been localized in synaptic vesicles and, recently, a Zn 2ϩ transporter (ZnT-3) that sequesters Zn 2ϩ into synaptic vesicles has been cloned (Palmiter et al., 1996; Wenzel et al., 1997) . Moreover, it is interesting to note that Zn 2ϩ levels in patients with Parkinson's disease are significantly elevated in substantia nigra, caudate nucleus and lateral putamen (Dexter et al., 1989) . Nevertheless, further studies are required to elucidate the physiological and/or pathophysiological relevance of the endogenous Zn 2ϩ site in hDAT. In summary, we have defined two coordinating residues in an endogenous Zn 2ϩ -binding site in hDAT and have thereby mapped an important distance constraint in the tertiary structure of a Na ϩ /Cl --dependent transporter. Identification of further coordinates in the Zn 2ϩ -binding site may add additional distance constraints that all together may prove an important scaffold for designing new artificial Zn 2ϩ sites. Hence, Zn 2ϩ site engineering may represent a significant new means for depicting the tertiary organization of this class of transporters.
Materials and methods

Site-directed mutagenesis
The cDNAs encoding hDAT and hNET were kindly provided by Dr Marc G.Caron (Duke University, Durham, NC). Mutant transporters were constructed by PCR-derived mutagenesis using Pfu polymerase according to the manufacturer's instructions (Stratagene, La Jolla, CA). The generated PCR fragments were digested with the appropriate enzymes, purified by agarose gel electrophoresis and cloned into the eukaryotic expression vector pRc/CMV, containing either hDAT or hNET (Pifl et al., 1993; Giros et al., 1994) . All mutations were confirmed by restriction enzyme mapping and DNA sequencing using the Thermo Sequenase fluorescent-labelled primer cycle sequencing kit with 7-deaza-dGTP on an Alfexpress™ DNA sequencer according to the manufacturer's instructions.
Expression of transporters in COS-7 cells
COS-7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) 041-31885 supplemented with 10% fetal calf serum, 2 mM L-glutamine and 0.01 mg/ml gentamicin. Wild-type and mutant constructs in pRc/CMV were transiently transfected into COS-7 cells by the calcium phosphate precipitation method as previously described (Johansen et al., 1990; Gether et al., 1992) .
[ 3 H]Dopamine uptake experiments Uptake assays were performed modified from Giros et al. (1992) using 2,5,6-[ 3 H]dopamine (7-21 Ci/mmol) (Amersham, Little Chalfont, UK). Transfected COS-7 cells were plated in either 24-well dishes (10 5 cells/ well) or 12-well dishes (2-3ϫ10 5 cells/well) to achieve an uptake level of 5-10% of total added [ 3 H]dopamine. The uptake assays were carried out 2 days after transfection. Prior to the experiment, the cells were washed once in 500 μl of uptake buffer (5 mM Tris-base, 7.5 mM HEPES, 120 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl 2 , 1.2 mM MgSO 4 , 1 mM L-ascorbic acid, 5 mM D-glucose, pH 7.1). The compound to be tested was added to the cells and uptake was initiated by addition of 10 nM [ 3 H]dopamine in a final volume of 500 μl. After 10 min of incubation at 37°C, the cells were washed twice with 500 μl of uptake buffer, lysed in 500 μl of 1% SDS and left for 1 h at 37°C. All samples were counted by liquid scintillation counting. Non-specific uptake was determined in the presence of 1 mM dopamine (RBI, Natick, MA). All determinations were performed in triplicate.
[ 
Calculations
Uptake and binding data were analysed by non-linear regression analysis using Inplot 4.0 or Prism 2.0 from GraphPad Software, San Diego, CA.
